Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R A Hauser

Showing results (91-100 of 92) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 92 results.
Parkinsonism & Related Disorders|November 5, 2013
Mobility, mood and site of care impact health related quality of life in Parkinson's diseaseJ G Nutt, A D Siderowf, M Guttman, et al.
Nature Aging|February 20, 2026
The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson's diseaseM H Werner, A McGarry, C Meyer, et al.
Pageof 10

Showing results (91-100 of 92) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 92 results.
Parkinsonism & Related Disorders|November 5, 2013
Mobility, mood and site of care impact health related quality of life in Parkinson's diseaseJ G Nutt, A D Siderowf, M Guttman, et al.
Nature Aging|February 20, 2026
The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson's diseaseM H Werner, A McGarry, C Meyer, et al.
Pageof 10